Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.
2.

Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.

Tawada A, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Ogasawara S, Suzuki E, Kanai F, Yoshikawa M, Yokosuka O.

Anticancer Res. 2015 Jan;35(1):549-54.

PMID:
25550601
3.

Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Oncology. 2011;80(3-4):188-94. doi: 10.1159/000328749. Epub 2011 Jun 27.

PMID:
21709428
4.

Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.

Okabe K, Beppu T, Haraoka K, Oh-Uchida Y, Yamamura S, Tomiyasu S, Yamanaka T, Sano O, Masuda T, Chikamoto A, Fujiyama S, Baba H.

Anticancer Res. 2011 Sep;31(9):2983-8.

PMID:
21868548
5.

Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.

Okimoto K, Ogasawara S, Chiba T, Ooka Y, Oobu M, Azemoto R, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yoshikawa M, Yokosuka O.

Anticancer Res. 2013 Dec;33(12):5603-9.

PMID:
24324105
6.

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Jpn J Clin Oncol. 2012 Mar;42(3):175-82. doi: 10.1093/jjco/hyr189. Epub 2011 Dec 30.

PMID:
22210921
7.

Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.

Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, Toshima F, Matsui O.

Jpn J Radiol. 2012 Apr;30(3):263-70. doi: 10.1007/s11604-011-0043-6. Epub 2012 Jan 7.

PMID:
22223074
8.

Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.

Matsumoto T, Ichikawa H, Imai J, Hayashi T, Tomita K, Mine T, Kojima S, Watanabe N, Hasebe T.

Anticancer Res. 2017 Jun;37(6):3183-3187.

PMID:
28551662
9.

[External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer].

Liu MZ, Wang XS, Cai L, Gu MF, Liu H, Li Q, Cui NJ, Zhang YQ, Li GH, Li JQ.

Ai Zheng. 2005 Jan;24(1):82-6. Chinese.

PMID:
15642207
11.

Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.

Seki A, Hori S.

Cardiovasc Intervent Radiol. 2012 Jun;35(3):555-62. doi: 10.1007/s00270-011-0176-0. Epub 2011 May 12.

PMID:
21562932
12.

Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy.

Hashimoto N, Iwazawa J, Ohue S, Mitani T.

Onco Targets Ther. 2013 Aug 1;6:1025-30. doi: 10.2147/OTT.S49443. eCollection 2013.

13.

Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.

Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M; Liver Cancer Study Group of Japan.

AJR Am J Roentgenol. 2010 Mar;194(3):830-7. doi: 10.2214/AJR.09.3308.

PMID:
20173167
14.

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K.

Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.

PMID:
21664811
15.

[Clinical evaluation of transcatheter arterial chemolipiodolization of miriplatin for multiple hepatocellular carcinoma].

Arai H, Kobayashi T, Izuka K, Ueno T, Mori K, Takizawa D, Toyoda M, Takayama H, Abe T.

Gan To Kagaku Ryoho. 2012 Dec;39(13):2513-6. Japanese.

PMID:
23235170
16.

Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.

Oguro S, Hashimoto S, Tanaka T, Inoue M, Nakatsuka S, Kuribayashi S, Asakura K, Kawachi S, Tanabe M, Kitagawa Y, Ebinuma H, Saito H, Hibi T.

Jpn J Radiol. 2012 Nov;30(9):735-42. doi: 10.1007/s11604-012-0116-1. Epub 2012 Aug 28.

PMID:
22923183
17.

Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization.

Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL.

Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1133-40. doi: 10.1007/s00270-008-9379-4. Epub 2008 Jun 27.

PMID:
18584240
19.

Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S.

J Gastroenterol. 2012 Feb;47(2):179-86. doi: 10.1007/s00535-011-0475-x. Epub 2011 Oct 6.

PMID:
21976133
20.

[Postoperative cholangitis of balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma].

Okabe K, Beppu T, Komori H, Sano O, Yamanaka T, Haraoka K, Ouchida Y, Fujiyama S, Baba H.

Gan To Kagaku Ryoho. 2014 Nov;41(12):2119-21. Japanese.

PMID:
25731442

Supplemental Content

Support Center